Peter Siesjö

Medicine & Life Sciences

1. Glioma 100%
2. Immunization 49%
3. Immunotherapy 48%
4. Neoplasms 43%
5. Brain Neoplasms 40%
6. Acoustic Neuroma 40%
7. Medulloblastoma 38%
8. Interferon-gamma 31%
9. Glioblastoma 27%
10. Aluminum 24%
11. Interleukin-7 23%
12. T-Lymphocytes 22%
13. Gentamicins 21%
14. Traumatic Brain Injury 15%
15. Granulocyte-Macrophage Colony-Stimulating Factor 15%
16. Nitric Oxide Synthase Type II 13%
17. Pituitary Neoplasms 13%
18. Ischemia 13%
19. Temozolomide 13%
20. Neurilemmoma 12%
21. Intracranial Pressure 12%
22. Cyclooxygenase 2 12%
23. Mesenchymal Stem Cells 11%
24. Therapeutics 11%
25. 4-chloro-3-(2,4-dihydroxyphenylazo)-2-hydroxybenzene-1-sulfonic acid 11%
26. Catheters 10%
27. Vitronectin 10%
28. Isografts 10%
29. antisecretory factor 9%
30. Theoretical Models 9%
31. Postural Balance 9%
32. Macrophages 9%
33. Child 9%
34. 2-mercaptoethylguanidine 8%
35. Nitric Oxide 8%
36. Adrenocorticotropic Hormone 8%
37. Leukocytes 8%
38. Oncogenes 8%
39. In Vitro Techniques 8%
40. Mitochondria 8%
41. Pediatrics 7%
42. Hydrocortisone 7%
43. Brain Stem Neoplasms 7%
44. Complement C9 7%
45. Drainage 7%
46. Hearing 7%
47. Dinoprostone 7%
48. Cytophagocytosis 7%
49. Preclinical Drug Evaluations 6%
50. Animals 6%